Xyzagen’s Christopher Crean Presented Long-Acting Anti-VEGF Research at ARVO 2025 in Salt Lake City

NEWS & EVENTS

Xyzagen’s Christopher Crean Presented Long-Acting Anti-VEGF Research at ARVO 2025 in Salt Lake City

Pittsboro, NC – May 8, 2025

Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced that its Founder and CEO, Christopher Crean, presented preclinical data on behalf of Optigo Biotherapeutics at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, held May 5–9, 2025, in Salt Lake City, Utah.

Christopher Crean, who also serves as Head of Preclinical Development for Optigo Biotherapeutics, presented a scientific poster titled:

Poster Title: Anchoring of Bispecific Anti-VEGF Molecules to Vitreous Components Extends Half-Life and Duration of Efficacy
Session Title: AMD: New Drugs, Delivery Systems, and Mechanisms of Action
Date & Time: Tuesday, May 6, 2025, from 3:30–5:15 PM (Mountain Time)

The study detailed the preclinical evaluation of Optigo’s innovative long-acting retina delivery platform, designed to reduce the burden of frequent intravitreal injections for patients with blinding neovascular diseases. By anchoring bispecific anti-VEGF molecules to native vitreous proteins, the research team achieved significant half-life extension and therapeutic durability in both rabbit and rat VEGF challenge models—supporting a potential dosing interval of 6 to 9 months.

“Reducing injection frequency while maintaining efficacy has long been a goal in retinal therapeutics,”

said Christopher Crean. “This work that we have helped manage for Optigo represents a key step forward in achieving more durable anti-VEGF treatments with real-world impact for patients.”

About Xyzagen

Talk to Xyzagen about how we can support your preclinical development program in pharmacology and pharmacokinetics within the ophthalmic field or other therapeutic disciplines, such as neurology. We also have toxicology consultants that we can contract with to support the preIND enabling toxicology program.

Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine.

Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. We’re a boutique organization which allows for small clients to work directly with experts during their critical decisions.